INTRODUCTION {#s1}
============

The *Pleomorphic adenoma gene* (*Plag*) family includes three genes: *Plag-like 1* (*Plagl1*; also known as *Zac1*), *Plag1* and *Plagl2*. *Plag* genes encode C~2~H~2~ Zn-finger transcription factors that are key regulators of tumorigenesis ([@BIO038661C1]; [@BIO038661C88]). *Zac1* was initially identified as a gene lost on transformation (*Lot1*) in a spontaneously transformed cell line ([@BIO038661C2]). Human *ZAC1* was subsequently found to be located on 6q24-25, a locus silenced in multiple carcinomas, including head and neck, ovarian, breast, kidney and pituitary tumors ([@BIO038661C3]; [@BIO038661C19]; [@BIO038661C22]; [@BIO038661C23]; [@BIO038661C53]; [@BIO038661C57]; [@BIO038661C60]; [@BIO038661C68]; [@BIO038661C70]; [@BIO038661C80]; [@BIO038661C83]; [@BIO038661C82], [@BIO038661C81]; [@BIO038661C90]). Consistent with its role as a tumor suppressor gene, *Zac1* promotes cell cycle exit and apoptosis *in vitro* in various cell lines ([@BIO038661C15]; [@BIO038661C67]; [@BIO038661C77]; [@BIO038661C90]) as well as *in vivo* in the developing nervous system ([@BIO038661C4]; [@BIO038661C63]; [@BIO038661C74]).

In contrast to *Zac1*, *Plag1* and *Plagl2* function as proto-oncogenes ([@BIO038661C42]). *Plag1* has been shown to be amplified in pleomorphic adenomas of the salivary gland ([@BIO038661C10]; [@BIO038661C11]; [@BIO038661C25]; [@BIO038661C33]; [@BIO038661C54]; [@BIO038661C55]; [@BIO038661C93]), lipoblastomas ([@BIO038661C12]; [@BIO038661C37]; [@BIO038661C45]; [@BIO038661C65]; [@BIO038661C72]), hepatoblastomas ([@BIO038661C101]) and some leukemias ([@BIO038661C58]; [@BIO038661C69]). The misexpression of *Plag1* in these cancers is due to chromosomal translocations that place *Plag1* under the control of regulatory elements for ubiquitously expressed genes, such as *Elongation factor SII gene* (*Tcea1*) ([@BIO038661C22]), *Ctnnb1* (*β-catenin*) ([@BIO038661C85]) and *Leukemia inhibitory factor receptor* (*Lifr*) ([@BIO038661C23]). *Plagl2* is similarly amplified in a number of cancers, including glioblastomas ([@BIO038661C104]) and acute myeloid leukemia ([@BIO038661C58]). Consistent with their roles as oncogenes, *Plag1* and *Plagl2* promote proliferation, anchorage-independent growth, loss of contact inhibition and tumor formation in mice ([@BIO038661C26], [@BIO038661C27]; [@BIO038661C42]; [@BIO038661C58]; [@BIO038661C89]; [@BIO038661C102]; [@BIO038661C104]). However, *Plagl2* is not oncogenic in all contexts as it is pro-apoptotic in response to hypoxia and other cellular stresses ([@BIO038661C36]; [@BIO038661C39]; [@BIO038661C52]; [@BIO038661C64]; [@BIO038661C98]).

All three members of the *Plag* gene family encode zinc finger transcription factors that share homology chiefly in their amino terminal zinc (Zn) finger domains, whereas the carboxyl terminal regions of the three proteins are quite diverse ([@BIO038661C56]). Several transcriptional targets of the Plag family transcription factors have been identified. For example, *Plag1* and *Plagl2* both regulate the expression of *Insulin-like Growth Factor 2* (*Igf2*), which accounts at least in part for their abilities to stimulate cell proliferation ([@BIO038661C21]; [@BIO038661C28]; [@BIO038661C90]; [@BIO038661C94]). In addition, *Plag1/Plagl2* promote tumorigenesis by initiating the transcription of several Wnt pathway genes. For instance, *Plagl2* has been shown to regulate expression of *Wnt6*, *Fzd2* and *Fzd9* to maintain cells in a proliferative state ([@BIO038661C104]). Likewise, *Plag1* misexpression in pleomorphic adenomas results in an upregulation of canonical Wnt signaling ([@BIO038661C28]; [@BIO038661C102]). Finally, *Plag1* was also found to regulate several cell division and cell cycle-related genes, such as *Cyclin D3* and *Cyclin D1*, as well as apoptosis-related genes, such as *Caspase-8* ([@BIO038661C95]).

Despite extensive knowledge of *Plag* gene function in cancer, their roles during normal development have only recently been examined. Z*ac1*, *Plag1* and *Plagl2* all function to regulate embryonic growth ([@BIO038661C43]; [@BIO038661C87]; [@BIO038661C91]). *Zac1* also controls development of keratinocytes ([@BIO038661C13]), heart ([@BIO038661C24]; [@BIO038661C99]) and pancreatic islets ([@BIO038661C8]), while *Plagl2* functions to control the development of enterocytes ([@BIO038661C87]). All three *Plag* genes are expressed in several lineages in the developing embryo as well as in some adult tissues, each with unique expression domains that overlap in certain lineages/tissues ([@BIO038661C6]; [@BIO038661C43]; [@BIO038661C71]; [@BIO038661C87]). For example, *Zac1* is expressed in a regionalized fashion in neural progenitor cells in the developing central (CNS) and peripheral (PNS) nervous systems, whereas *Plag1* and *Plagl2* are more uniformly expressed in CNS and PNS neural progenitors ([@BIO038661C1]; [@BIO038661C6]; [@BIO038661C11]; [@BIO038661C70]). Interestingly, all three *Plag* genes are co-expressed at higher levels in neural progenitors than in post-mitotic neurons ([@BIO038661C6]; [@BIO038661C71]).

*Plag1* null mice (*Plag1*^KI/KI^), although viable, are growth retarded and have reduced fertility ([@BIO038661C43]). However, despite their growth defects and the known ability of *Plag1* to regulate expression of the *Igf2* growth factor ([@BIO038661C94]), *Igf2* expression levels were found to be unperturbed in *Plag1* null mice ([@BIO038661C43]). Thus, the underlying molecular mechanisms that lead to growth perturbation in *Plag1* null embryos remain unknown. Likewise, *Plagl2* mutant neonates also weigh less relative to their littermates at birth ([@BIO038661C87]). However, unlike *Plag1* mutants, *Plagl2* mutant pups display postnatal lethality, dying shortly after birth due to starvation and nutrient malabsorption ([@BIO038661C87]). In the neonatal *Plagl2* mutant liver, the starvation response factor *asparagine synthetase* is expressed at high levels ([@BIO038661C87]), whereas *Igf1* levels are low, indicative of a loss of nutrients.

In the CNS, multiple developmental roles for *Zac1* have been deciphered, including in the retina, cerebellum and neocortex ([@BIO038661C4]; [@BIO038661C20]; [@BIO038661C62],[@BIO038661C63]; [@BIO038661C74]). However, to date, neither *Plag1* nor *Plagl2* have any known functions in the developing CNS. Here, given their overlapping expression with *Zac1*, we asked whether *Plag1* and *Plagl2*, also function during neocortical development, revealing novel and specific roles for these genes in both telencephalic patterning and in regulating neocortical progenitor cell proliferation and neurogenesis.

RESULTS {#s2}
=======

*Plag1* and *Plagl2* do not cross-regulate each other at the level of transcription {#s2a}
-----------------------------------------------------------------------------------

*Plag1* and *Plagl2* have similar amino acid sequences, sharing 79% and 35% identity in their N- and C-termini, respectively ([@BIO038661C52]). They also share several transcriptional targets, including the growth factor *Igf2* ([@BIO038661C1]). In addition, *Plag1* and *Plagl2* have both been characterized as growth regulators and proto-oncogenes ([@BIO038661C1]; [@BIO038661C52]; [@BIO038661C58]). Here we set out to determine whether they also have overlapping and possibly redundant roles in the developing telencephalon.

To better understand how *Plag1* and *Plagl2* function in the embryonic telencephalon, we first examined their expression profiles at embryonic day (E) 12.5, when the first neurons have begun to differentiate in both dorsal and ventral domains ([@BIO038661C5]). As previously reported ([@BIO038661C6]), *Plag1* ([Fig. 1](#BIO038661F1){ref-type="fig"}A) and *Plagl2* ([Fig. 1](#BIO038661F1){ref-type="fig"}C) were expressed in E12.5 telencephalic progenitors throughout the dorsal and ventral ventricular zones (VZ) in a highly similar fashion, albeit with apparently higher *Plagl2* transcript levels. We also monitored the expression of these genes by taking advantage of the knockin of *lacZ* into the *Plag1* \[*Plag1^lacZ^*^KI/+^; [Fig. 1](#BIO038661F1){ref-type="fig"}E; [@BIO038661C43]\] and *Plagl2* \[*Plagl2^lacZ^*^KI/+^; [Fig. 1](#BIO038661F1){ref-type="fig"}F; [@BIO038661C87]\] loci. X-gal staining of coronal sections of E12.5 *Plag1^lacZ^*^KI/+^ (hereafter *Plag1*^KI/+^; [Fig. 1](#BIO038661F1){ref-type="fig"}G) and *Plagl2^lacZ^*^KI/+^ (hereafter *Plagl2*^KI/+^; [Fig. 1](#BIO038661F1){ref-type="fig"}H) heterozygous brains revealed that *lacZ* had a similar distribution throughout the telencephalic VZ in both genotypes, again with apparently higher levels of *lacZ* expression in *Plagl2*^KI/+^ cortices. *Plag1* and *Plagl2* are thus expressed similarly in the early embryonic telencephalic VZ, an expression profile that we previously demonstrated persists into the late embryonic period ([@BIO038661C6]). Fig. 1.***Plag1* and *Plagl2* have similar patterns of telencephalic gene expression and function redundantly to regulate embryonic development.** (A--D) Expression of *Plag1* (A,B) and *Plagl2* (C,D) in E12.5 wild-type (A,C), *Plagl2^lacZ^*^KI/KI^ (B) and *Plag1^lacZ^*^KI/KI^ (D) whole heads. (E,F) Schematic representations of genetic mutations in *Plag1^lacZ^*^KI/KI^ (E) and *Plagl2^lacZ^*^KI/KI^ (F) mice (G,H) X-gal staining of E12.5 *Plagl^lacZ^*^KI/+^ (G) and *Plagl2^lacZ^*^KI/+^ (H) brains. (I--J″) Schematic representation of RT-qPCR experiment (I). Analysis of *Plag1* (J), *Plagl2* (J′) and *Plagl1*/*Zac1* (J″) transcript levels in E12.5 wild-type, *Plag1*^KI/KI^ and *Plagl2*^KI/KI^ cortices. ns, not significant; \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.005. (L,M) Punette square analysis of the ratios of genotypes acquired from *Plag1*^KI/+^;*Plagl2*^KI/+^ heterozygous intercrosses (L). Graphical representation of the expected (black bars) and observed (blue bars) numbers of embryos with each genotype (M). cx, neocortex; lge, lateral ganglionic eminence; mge, medial ganglionic eminence; oe, olfactory epithelium; pp, preplate; re, retina; vz, ventricular zone. Scale bars: 250 μm.

In several instances, highly related genes in the same family are not only expressed in the same CNS domains, but also display cross-regulatory interactions. For example, the highly similar proneural genes *Neurog1* and *Neurog2* are largely co-expressed in the early embryonic dorsal telencephalon ([@BIO038661C16]; [@BIO038661C41]), and *Neurog2* is required to initiate *Neurog1* expression in the dorsomedial cortex ([@BIO038661C35]). To determine whether there are similar cross-regulatory interactions between *Plag1* and *Plagl2* in the developing telencephalon, we asked whether mutation of one gene can alter expression of the other gene. By RNA *in situ* hybridization, we observed a similar distribution of *Plag1* transcripts in the telencephalic VZ of E12.5 *Plagl2*^KI/KI^ homozygous mutants as seen in wild-type brains ([Fig. 1](#BIO038661F1){ref-type="fig"}A,B). The converse was also true, as *Plagl2* transcripts were maintained in the telencephalic VZ of E12.5 *Plag1*^KI/KI^ homozygous mutants in a similar pattern as in wild-type brains ([Fig. 1](#BIO038661F1){ref-type="fig"}C,D).

To validate that there were no differences in *Plag1* and *Plagl2* transcript levels in homozygous mutants for the other *Plag* gene, we micro-dissected out telencephalic tissue at E12.5 and performed RT-qPCR ([Fig. 1](#BIO038661F1){ref-type="fig"}I). As expected, *Plag1* transcripts were not detectable in *Plag1*^KI/KI^ cortices, whereas *Plag1* transcript levels were at the same relative level in wild-type controls and in E12.5 *Plagl2*^KI/KI^ homozygous mutant cortices ([Fig. 1](#BIO038661F1){ref-type="fig"}J). Similarly, *Plagl2* transcripts were not detectable in cortical tissue from *Plagl2*^KI/KI^ homozygous mutants, whereas *Plagl2* transcripts were expressed at wild-type levels in E12.5 *Plag1*^KI/KI^ cortices ([Fig. 1](#BIO038661F1){ref-type="fig"}J′). To complete this data set, we also analyzed expression levels of the third member of this gene family, *Plagl1* (also known as *Zac1*), which differs in that it is a tumor suppressor gene ([@BIO038661C1]). *Zac1* is expressed at high levels in neocortical progenitors and plays a role in regulating neuronal morphology and migration ([@BIO038661C4]). While no differences in *Zac1* transcript levels were observed in *Plag1*^KI/KI^ cortices, there was a small but significant reduction in *Zac1* expression in *Plagl2*^KI/KI^ dorsal telencephalic tissue ([Fig. 1](#BIO038661F1){ref-type="fig"}J″, *P*\<0.01, *n*=3). Finally, a comparison of relative transcript levels (normalized to the same housekeeping genes) revealed that *Zac1* is expressed at the highest levels in cortical cells, followed by *Plagl2* and *Plag1*.

Thus, all three *Plag* genes are expressed in cortical progenitors, and while there is no evidence of cross-regulatory transcriptional interactions between *Plag1* and *Plagl2*, *Zac1* levels are reduced in *Plagl2* mutants, at least at E12.5, which is the stage we focused on for the remainder of this study.

*Plag1* and *Plagl2* act redundantly to control embryonic survival {#s2b}
------------------------------------------------------------------

Previous reports have suggested that *Plag1*^KI/KI^ null mice are viable after birth, but are growth retarded and have reduced fertility ([@BIO038661C43]). Likewise, *Plagl2*^KI/KI^ neonates weigh less relative to their littermates at birth ([@BIO038661C87]). However, unlike *Plag1*^KI/KI^ mutants, *Plagl2^KI/KI^* pups display postnatal lethality, dying shortly after birth due to starvation and nutrient malabsorption ([@BIO038661C87]). To determine whether *Plag1* and *Plagl2* function redundantly or have distinct functions in the embryonic telencephalon, we set out to generate double mutants by setting up double heterozygous intercrosses between *Plag1*^KI/+^;*Plagl2*^KI/+^ male and female mice. We collected seventeen litters at E12.5 for a total of 120 live embryos and compared the acquired genotypes to the expected genotypes using a Mendelian Punette square diagram for a dihybrid cross ([Fig. 1](#BIO038661F1){ref-type="fig"}L). If there was no embryonic lethality, we expected Mendelian ratios for each possible genotype after double heterozygous intercrosses. Of the 120 embryos genotyped, significantly under-represented genotypes included *Plag1^+/+^;Plagl2^KI/KI^*, *Plag1^KI/+^;Plagl2^KI/KI^* and *Plag1^KI/KI^;Plagl2^KI/KI^* ([Fig. 1](#BIO038661F1){ref-type="fig"}M).

As we did not collect any double mutant embryos, our data suggests that *Plag1* and *Plagl2* function redundantly to control embryonic survival. Moreover, the *Plagl2^KI/KI^* genotype has an early embryonic lethal phenotype. This finding was somewhat surprising given that *Plagl2^KI/KI^* mutant embryos were previously reported to survive postnatally ([@BIO038661C87]). Differences between the two studies are likely related to our use of a different genetic background (i.e. CD1) compared to 129/SvJ background used by [@BIO038661C87].

*Plagl2* is required to set the positioning of ventral gene expression at the pallial-subpallial border {#s2c}
-------------------------------------------------------------------------------------------------------

Neuronal fate specification is directly linked to dorsoventral regional identity in the telencephalon, with progenitors in the dorsal telencephalon giving rise to glutamatergic excitatory projection neurons, while ventral progenitors give rise to GABAergic inhibitory interneurons ([@BIO038661C75]). Given that *Plag1* and *Plagl2* were expressed in both dorsal and ventral telencephalic progenitors, we first asked whether the *Plag* genes acted upstream of regional patterning genes. Genes involved in the initial patterning of telencephalic domains are expressed in a regionalized manner and are enriched in, or restricted to, precise dorsal or ventral telencephalic progenitor domains, displaying sharp dorsoventral boundaries ([@BIO038661C46]). Mutation of several patterning genes can disrupt the positioning of borders between dorsal and ventral domains, ultimately affecting the generation of the brain territories derived from these regionalized progenitors. For instance, mutation of the homeobox gene *Gsx2* results in an expansion of dorsal telencephalic (pallial) territories and a corresponding reduction in ventral telencephalic (subpallial) territories, whereas *Pax6* mutants have the opposite phenotype ([@BIO038661C100]).

To assess the roles of the *Plag* genes in dorsoventral patterning, we focused on *Plag1* and *Plagl2* single mutants as we were not able to generate E12.5 *Plag1;Plagl2* double mutants. In these embryos, we compared the position of the dorsoventral border between high and low gene expression in the telencephalon (red arrowheads; [Fig. 2](#BIO038661F2){ref-type="fig"}C--K) to a morphological landmark, the corticostriatal angle (black arrowheads; [Fig. 2](#BIO038661F2){ref-type="fig"}C--K). To provide quantitative measurements of regional differences, we measured the length ([Fig. 2](#BIO038661F2){ref-type="fig"}A) and angle ([Fig. 2](#BIO038661F2){ref-type="fig"}B) between the corticostriatal border (morphological landmark) and the pallial-subpallial boundary (PSPB, gene expression landmark), using a fixed lever length for angle measurements. Fig. 2.***Plag1* and *Plagl2* are required to pattern the embryonic telencephalon.** (A,B) Schematic representations of length (A) and angle (B) measurements of the ventral pallium, extending from the corticostriatal angle to the gene expression border. (C--K) Expression of *Ascl1* (C--E), *Dlx1* (F--H) and *Neurog2* (I--K) in E12.5 wild-type (C,F,I), *Plag1*^KI/KI^ (D,G,J) and *Plagl2*^KI/KI^ (E,H,K) brains. Black arrowheads mark the corticostriatal angle and red arrowheads mark the ventral pallial gene expression limit. (L--O) Quantification of the length (L,N) and angle (M,O) of the ventral pallium based on the expression of *Ascl1* (L,M), and *Neurog2* (N,O). Error bars are s.e.m. ns, not significant; \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.005. ch, cortical hem; cx, neocortex; dlge, dorsal lateral ganglionic eminence; dp, dorsal pallium; lge, lateral ganglionic eminence; lp, lateral pallium; mge, medial ganglionic eminence; mp, medial pallium; oe, olfactory epithelium; re, retina; vlge, ventral lateral ganglionic eminence; vp, ventral pallium. Scale bars: 250 μm.

We first examined the expression of *Ascl1*, a proneural gene encoding a basic-helix-loop-helix (bHLH) transcription factor that is required for ventral telencephalic development ([@BIO038661C17]). At E12.5, *Ascl1* was expressed at high levels in the ventral telencephalic VZ, including in both the lateral (LGE) and medial (MGE) ganglionic eminences ([Fig. 2](#BIO038661F2){ref-type="fig"}C), as previously reported ([@BIO038661C17]). *Ascl1* transcripts were also enriched in the cortical hem, while lower levels of *Ascl1* transcripts were detected in the dorsal telencephalic VZ ([Fig. 2](#BIO038661F2){ref-type="fig"}C). The dorsal most limit of the high *Ascl1*-expression domain marked the PSPB; immediately ventral to the PSPB was an *Ascl1*-high subpallial territory known as the dorsal LGE (dLGE) and immediately dorsal to the PSPB was an *Ascl1*-low pallial territory known as the ventral pallium ([@BIO038661C100]) ([Fig. 2](#BIO038661F2){ref-type="fig"}C). A similar pattern of expression was observed in E12.5 *Plag1*^KI/KI^ mutant brains ([Fig. 2](#BIO038661F2){ref-type="fig"}D), while the high *Ascl1* expression domain appeared to shift ventrally in E12.5 *Plagl2*^KI/KI^ cortices ([Fig. 2](#BIO038661F2){ref-type="fig"}E). Indeed, measurement of the length (*n*=3; *P*\<0.01; [Fig. 2](#BIO038661F2){ref-type="fig"}L) and angle (*n*=3; *P*\<0.01; [Fig. 2](#BIO038661F2){ref-type="fig"}M) between the corticostriatal angle and the limit of the high *Ascl1* expression domain confirmed that these values were greater in the E12.5 *Plagl2* telencephalon compared to wild-type brains.

To provide further validation for this finding, we also examined the expression of *Dlx1*, a homeodomain transcription factor that acts with the related gene *Dlx2* to establish a ventral telencephalic identity, with the absence of these genes, resulting in the loss of most if not all GABAergic interneurons ([@BIO038661C7]). In E12.5 wild-type brains, *Dlx1* was expressed at high levels throughout the VZ of the LGE and MGE, with its dorsal limit in the dLGE, and no expression in the ventral pallium ([Fig. 2](#BIO038661F2){ref-type="fig"}F). A similar pattern of expression was observed in the E12.5 *Plag1*^KI/KI^ telencephalon ([Fig. 2](#BIO038661F2){ref-type="fig"}G), whereas in E12.5 *Plagl2*^KI/KI^ brains ([Fig. 2](#BIO038661F2){ref-type="fig"}H), the dorsal limit of the *Dlx1* expression domain was positioned more ventrally.

Taken together, these data suggest that *Plagl2* is required to maintain the position of the PSPB in the E12.5 telencephalon, a contention that we investigated further with additional marker analysis.

*Plagl2* is required to set the positioning of dorsal gene expression at the pallial-subpallial border {#s2d}
------------------------------------------------------------------------------------------------------

We next examined the expression of dorsally-restricted genes in E12.5 *Plag1* and *Plagl2* mutants. The proneural gene *Neurog2*, which also encodes a bHLH transcription factor, is required to specify a dorsal telencephalic identity ([@BIO038661C35]). In the E12.5 wild-type telencephalon, *Neurog2* was exclusively expressed in the dorsal telencephalic VZ, with the ventral border of expression extending into the ventral pallium and ending at the PSPB ([Fig. 2](#BIO038661F2){ref-type="fig"}I). A similar pattern of *Neurog2* expression was observed in the E12.5 *Plag1*^KI/KI^ ([Fig. 2](#BIO038661F2){ref-type="fig"}J) telencephalon, while the limit of *Neurog2* expression extended ventrally in *Plagl2*^KI/KI^ brains ([Fig. 2](#BIO038661F2){ref-type="fig"}K). We validated these observations by performing measurements of the length (*n*=3; *P*\<0.01; [Fig. 2](#BIO038661F2){ref-type="fig"}N) and angle (*n*=3; *P*\<0.01; [Fig. 2](#BIO038661F2){ref-type="fig"}O) between the corticostriatal angle and the limit of high *Neurog2* expression.

To further examine the position of the PSPB, we performed co-staining of a dorsal pallial marker, the homeodomain transcription factor Pax6, and a ventral marker, the homeodomain transcription factor Gsx2 ([Fig. 3](#BIO038661F3){ref-type="fig"}). While Pax6 expression extends into the Gsx2^+^ dLGE territory at E10.5, resulting in the co-expression of these two transcription factors in the dLGE ([@BIO038661C100]), we found that at E12.5, Pax6 and Gsx2 expression domains directly abutted one another at the PSPB; Pax6 was expressed at high levels throughout the pallium, including in the ventral pallium, whereas Gsx2 was expressed exclusively in the LGE and MGE, including in the dLGE ([Fig. 3](#BIO038661F3){ref-type="fig"}A,D--D‴). A similar pattern of co-expression was observed in E12.5 *Plag1*^KI/KI^ telencephalons; high Pax6 expression in the pallium and Gsx2 expression restricted to the LGE/MGE, with little to no overlap at the PSPB ([Fig. 3](#BIO038661F3){ref-type="fig"}B,E--E‴). In contrast, in the *Plagl2*^KI/KI^ telencephalon Pax6 expression extended further ventrally, while the Gsx2 expression limit was restricted to a more ventral position, but there was still limited overlap between these markers ([Fig. 3](#BIO038661F3){ref-type="fig"}C,F--F‴). To confirm these apparent differences in expression, we quantitated the distance between the corticostriatal angle and the border between the Gsx2 and Pax6 expression domains (presumptive PSPB; [Fig. 3](#BIO038661F3){ref-type="fig"}G), revealing that this distance was indeed larger in the *Plagl2*^KI/KI^ telencephalon (*n*=3; *P*\<0.05; [Fig. 3](#BIO038661F3){ref-type="fig"}H). Fig. 3.***Plagl2* is required to maintain the pallial-subpallial boundary in the developing telencephalon.** (A--F) Expression of Pax6 (green), Gsh2 (red) and DAPI (blue) in E12.5 wild-type (A,D--D‴), *Plag1*^KI/KI^ (B,E--E‴) and *Plagl2*^KI/KI^ (C,F--F‴) brains. (D′--F‴) Higher magnification images of Pax6 (D′--F′), Gsh2 (D″--F″) and DAPI (D‴--F‴) in E12.5 wild-type (D′--D‴), *Plag1*^KI/KI^ (E′--E‴) and *Plagl2*^KI/KI^ (F′--F‴) brains. White arrowheads mark the corticostriatal angle. Red arrowheads mark the ventral pallium-dlge boundary. (G) Schematic illustration of the length measurement of the ventral pallium. (H) Quantification of the length of the ventral pallium. Error bars are s.e.m. ns, not significant; \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.005. ch, cortical hem; cx, neocortex; dlge, dorsal lateral ganglionic eminence; dp, dorsal pallium; lge, lateral ganglionic eminence; lp, lateral pallium; mge, medial ganglionic eminence; mp, medial pallium; oe, olfactory epithelium; re, retina; vlge, ventral lateral ganglionic eminence; vp, ventral pallium. Scale bars: 250 μm.

Expansion of the ventral pallium in *Plagl2* mutants {#s2e}
----------------------------------------------------

The shift in the positioning of the PSPB could mean that there was an expansion in the size of the ventral pallium, and possibly a corresponding reduction in the size of the dLGE, as observed in *Gsx2* mutants ([@BIO038661C100]). To test this possibility more fully, we examined the expression of markers that specifically label these two regional territories, using *Dbx1* to label the ventral pallium ([@BIO038661C14]), and *Etv1/ER81* ([@BIO038661C100]) and *Sp8* ([@BIO038661C96]) to mark the dLGE. In E12.5 wild-type cortices, *Dbx1* labeled a small stripe of cells ventral to the corticostriatal angle, which is the ventral pallium ([Fig. 4](#BIO038661F4){ref-type="fig"}A,A′). The *Dbx1*^+^ ventral pallial territory was of a similar size and position in E12.5 *Plag1*^KI/KI^ brains ([Fig. 4](#BIO038661F4){ref-type="fig"}B,B′). In contrast, in E12.5 *Plagl2*^KI/KI^ brains, *Dbx1* expression initiated in the same position just ventral to the corticostriatal angle, but it extended further ventrally, consistent with the idea that the ventral pallium is expanded in size in *Plagl2* mutants ([Fig. 4](#BIO038661F4){ref-type="fig"}C,C′). Finally, to determine whether there was a compensatory decrease in the size of the dLGE, we examined the expression of *Sp8*, which marked a thin, similarly sized ventral stripe of cells in both E12.5 wild-type ([Fig. 4](#BIO038661F4){ref-type="fig"}D,D′) and *Plagl2*^KI/KI^ ([Fig. 4](#BIO038661F4){ref-type="fig"}E,E′) brains. In addition, no noticeable differences were observed in the *Etv1*^+^ dLGE domain size in E12.5 wild-type ([Fig. 4](#BIO038661F4){ref-type="fig"}F,F′) and *Plagl2*^KI/KI^ ([Fig. 4](#BIO038661F4){ref-type="fig"}G,G′) brains. Fig. 4.***Plagl2* is required to regulate the ventral pallium boundary in the developing telencephalon.** (A--C′) Expression of the ventral pallial gene, *Dbx1*, in E12.5 wild-type (A,A′), *Plag1*^KI/KI^ (B,B′) and *Plagl2*^KI/KI^ (C,C′) telencephalons. (D--G′) Expressions of the dlge markers, *Sp8* (D--E′) and *Etv1* (F--G′) in E12.5 wild-type (D,D′,F,F′) and *Plagl2*^KI/KI^ (E,E′,G,G′) telencephalons. Black arrowheads mark the corticostriatal angle. Red arrowheads mark the dorsal limit of gene expression. (H--K) Schematic illustration of the pallial-subpallial boundary between the ventral pallium and dlge in E12.5 wild-type (H,I), *Plag1*^KI/KI^ (J) and *Plagl2*^KI/KI^ (K), showing positioning defects in the *Plagl2*^KI/KI^ brains. dlge, dorsal lateral ganglionic eminence; vp, ventral pallium. Scale bars: 250 μm.

Taken together these data support the idea that only the ventral pallium is expanded in *Plagl2* mutants, without a corresponding change in dLGE size ([Fig. 4](#BIO038661F4){ref-type="fig"}H--K).

Altered positioning of the pallial-subpallial border extends into intermediate neuronal progenitors but does not affect the number of early-born piriform cortex neurons {#s2f}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Until now, our marker analyses were restricted to VZ progenitors, which are primarily radial glial cells (RGCs) that serve as progenitors for glutamatergic neurons \[reviewed in [@BIO038661C97]\]. We next asked whether the expansion of the pallial domains in *Plagl2* mutants translated into differences in secondary pallial progenitors, the Tbr2^+^ intermediate neuronal progenitors (INPs) that are derived from Pax6^+^ RGCs ([@BIO038661C32]). Although Tbr2 is expressed in the subventricular zone (SVZ), it has the same dorsoventral regional borders as *Neurog2* and Pax6, terminating at the ventral limit of the ventral pallium with no expression observed in the dLGE in E12.5 wild-type telencephalons ([Fig. 5](#BIO038661F5){ref-type="fig"}A,A′). A similar pattern of Tbr2 expression was observed in E12.5 *Plag1*^KI/KI^ brains ([Fig. 5](#BIO038661F5){ref-type="fig"}B,B′), whereas in E12.5 *Plagl2*^KI/KI^ telencephalons, Tbr2 expression extended further ventrally ([Fig. 5](#BIO038661F5){ref-type="fig"}C,C′). These data thus suggest that the increased size of the ventral pallial territory extends from VZ progenitors and into SVZ progenitors in E12.5 *Plagl2*^KI/KI^ telencephalons ([Fig. 5](#BIO038661F5){ref-type="fig"}G--G″). Fig. 5.**Tbr2 expression in intermediate neuronal progenitors in the ventral pallium shifts ventrally in *Plagl2* mutants.** (A--C′) Tbr2 expression in E12.5 wild-type (A,A′), *Plag1*^KI/KI^ (B,B′) and *Plagl2*^KI/KI^ (C,C′) telencephalons. (D--F′) Tbr1 expression in E12.5 wild-type (D,D′), *Plag1*^KI/KI^ (E,E′) and *Plagl2*^KI/KI^ (F,F′) telencephalons. White arrowheads mark the corticostriatal angle. Red arrowheads mark the ventral limit of high dorsal gene expression. (G--G″) Schematic illustration of ventral pallial domain in wild-type (G,Gʹ) and *Plagl2*^KI/KI^ (G″) telencephalons. (H--Hʹ) Schematic illustration of the Tbr1 piriform cortex (blue) that was used for quantification. (I) Quantification of the Tbr1^+^/DAPI^+^ cells in the presumptive piriform cortex. Error bars are s.e.m. ns, not significant. cx, neocortex; dlge, dorsal lateral ganglionic eminence; lge, lateral ganglionic eminence; mge, medial ganglionic eminence; pc, piriform cortex; vp, ventral pallium. Scale bars: 250 μm.

Finally, we asked whether there was a corresponding shift in the expression domain of Tbr1, which marks postmitotic projection neurons that are derived from pallial territories, including the ventral pallium, which gives rise to Cajal-Retzius neurons that cover the pallial surface, and to neurons that populate the presumptive piriform cortex ([@BIO038661C31]; [@BIO038661C100]). We first focused on the Tbr1^+^ mantle zone in the presumptive piriform cortex, which extended in a wedge shape from the pial surface towards the limit of the SVZ at the corticostriatal angle in E12.5 wild-type embryos ([Fig. 5](#BIO038661F5){ref-type="fig"}D,D′,H,H′). Similar patterns of Tbr1 expression were observed in the mantle of the piriform cortex in E12.5 *Plag1*^KI/KI^ ([Fig. 5](#BIO038661F5){ref-type="fig"}E,E′) and *Plagl2*^KI/KI^ ([Fig. 5](#BIO038661F5){ref-type="fig"}F,F′) brains, with no reduction in the total number of Tbr1^+^ cells (*n*=3; *P*\>0.05 for all comparisons; [Fig. 5](#BIO038661F5){ref-type="fig"}I).

Taken together, these data suggest that *Plagl2* is required to maintain the position of the border between the ventral pallium and dLGE at the primary VZ progenitor and secondary SVZ progenitor stage. While there was no obvious reduction in the size of the Tbr1^+^ neuronal pool in the mantle of the presumptive piriform cortex, the complex migration patterns of ventral pallium-derived neurons, which include Cajal-Retzius neurons that migrate tangentially to cover the pallial surface ([@BIO038661C14]), makes it difficult to specifically assess neuronal output from the ventral pallium.

*Plag1* is required to regulate the differentiation and proliferation of early embryonic neocortical progenitors {#s2g}
----------------------------------------------------------------------------------------------------------------

To further assess the functions of the *Plag* genes in the developing telencephalon, we next focused on dorsal pallial territories, which give rise to the neocortex. To first ask whether *Plag1* and *Plagl2* were required to regulate the proliferation of neocortical progenitors, we administered BrdU 30 min prior to sacrifice to label progenitor cells in S-phase of the cell cycle. In E12.5 wild-type ([Fig. 6](#BIO038661F6){ref-type="fig"}A), *Plag1*^KI/KI^ ([Fig. 6](#BIO038661F6){ref-type="fig"}B) and *Plagl2*^KI/KI^ ([Fig. 6](#BIO038661F6){ref-type="fig"}C) cortices, BrdU was detected in an abventricular band where S-phase progenitors accumulate due to interkinetic nuclear migration. Quantitation revealed that there was a 1.67-fold reduction in the percentage of S-phase progenitors in the *Plag1*^KI/KI^ cortex (*n*=3; *P*\<0.01), whereas there was no change in the BrdU labeling index in the *Plagl2*^KI/KI^ cortex ([Fig. 6](#BIO038661F6){ref-type="fig"}D). Similarly, labeling G2/M-phase progenitors with phospho-histone H3 (pHH3), which marks mitotic cells near the apical surface in E12.5 wild-type ([Fig. 6](#BIO038661F6){ref-type="fig"}E), *Plag1*^KI/KI^ ([Fig. 6](#BIO038661F6){ref-type="fig"}F) and *Plagl2*^KI/KI^ ([Fig. 6](#BIO038661F6){ref-type="fig"}G) cortices, revealed a threefold reduction in pHH3^+^ cells in *Plag1* mutants ([Fig. 6](#BIO038661F6){ref-type="fig"}H). Fig. 6.***Plag1* is required to regulate proliferation in the early embryonic telencephalon.** (A--T) Analysis of the expression of BrdU (A--C), pHH3 (E--G), Pax6 (I--K), Tbr2 (M--O) and Tbr1 (Q--S) in E12.5 wild-type (A,E,I,M,Q), *Plag1*^KI/KI^ (B,F,J,N,R) and *Plagl2*^KI/KI^ (C,G,K,O,S) cortices. Quantification of the percentage of DAPI^+^ cells expressing BrdU (D), pHH3 (H), Pax6 (L), Tbr2 (P) and Tbr1 (T). Error bars are s.e.m. ns, not significant; \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.005. pp, preplate; vz, ventricular zone. Scale bars: 125 μm.

Taken together, these data suggest that *Plag1*, and not *Plagl2*, is required to regulate the number of cycling progenitors in S- and G2/M-phases of the cell cycle. We next assessed changes in the expression of progenitor cell markers in E12.5 wild-type ([Fig. 6](#BIO038661F6){ref-type="fig"}I,M), *Plag1*^KI/KI^ ([Fig. 6](#BIO038661F6){ref-type="fig"}J,N) and *Plagl2*^KI/KI^ ([Fig. 6](#BIO038661F6){ref-type="fig"}K,O) cortices, using Pax6 to label RGCs ([@BIO038661C34]) and the T-box transcription factor Tbr2 to label INPs ([@BIO038661C9]; [@BIO038661C76]). Pax6 labeled the same number of RGC progenitors in the VZ in all genotypes ([Fig. 6](#BIO038661F6){ref-type="fig"}I--L), and Tbr2 labeled the same number of INPs ([Fig. 6](#BIO038661F6){ref-type="fig"}M--P). The decrease in VZ proliferation in *Plag1* mutants was therefore not translated into an overall change in progenitor cell number, at least by E12.5.

Changes in the BrdU and pHH3-labelling indices in *Plag1* mutants might reflect alterations in the ratios between proliferative and differentiating populations rather than changes in proliferation rates. We therefore examined whether *Plag1* and/or *Plagl2* regulated the differentiation of neocortical progenitors by examining the expression of Tbr1, a marker of early-born, deep-layer neurons ([@BIO038661C44]). There was a small but significant increase in the number of early-born neurons generated in E12.5 *Plag1*^KI/KI^ mutants compared to wild type, whereas there were no significant changes in Tbr1 expression in the *Plagl2*^KI/KI^ cortices relative to wild type ([Fig. 6](#BIO038661F6){ref-type="fig"}Q--T). Notably, the differences in proliferation and differentiation observed in *Plag1*^KI/KI^ mutants did not translate into alterations in the total number of DAPI^+^ nuclei in the E12.5 neocortex (wild type: 1393±76.4; *Plag1*^KI/KI^: 1188±68.8; *Plagl2*^KI/KI^: 1427±80.0; *n*=3 for each genotype).

Taken together we can conclude that *Plag1* is required to maintain the balanced choice between proliferation and differentiation in the E12.5 neocortex, suggesting that *Plagl2*, which is not mutated (or altered in expression) in *Plag1*^KI/KI^ embryos, is not sufficient to rescue this phenotype. In contrast, *Plagl2* is not required for the proliferation or differentiation of neocortical progenitors, possibly because *Plag1* and altered *Zac1* expression levels compensate to some extent for *Plagl2* functions.

*Plagl2* increases the BrdU labelling index within 24 h post-electroporation {#s2h}
----------------------------------------------------------------------------

*Plag1* and *Plagl2* are both proto-oncogenes, promoting cell proliferation in a malignant context ([@BIO038661C1]; [@BIO038661C88]). We therefore asked whether the overexpression of these factors in non-transformed, embryonic neural progenitors could similarly promote proliferation, and/or alter differentiation. For this purpose, we used *in utero* electroporation to introduce *Plag1* and/or *Plagl2* expression constructs containing an IRES-GFP cassette into dorsal telencephalic progenitors at E12.5, or an empty vector control expressing GFP only. Embryos were harvested 24 h post-electroporation and transfected cells were identified using GFP epifluorescence ([Fig. 7](#BIO038661F7){ref-type="fig"}A). Fig. 7.***Plagl2* is sufficient to alter the proliferation of neocortical progenitors within 24 h post-electroporation.** (A) Schematic representation of gain-of-function experiment using *in utero* electroporation. (B--Q) E12.5 to E13.5 electroporations of pCIG2 (B,F,J,N), *Plag1* (C,G,K,O) and *Plagl2* (D,H,L,P) analyzed for the expression of BrdU (B--D), pHH3 (F--H), Pax6 (J--L), Tbr2 (N--P). Quantitation of the ratios of GFP^+^ cells that are BrdU^+^ (E), pHH3^+^ (I), Pax6^+^ (M) and Tbr2^+^ (Q). Error bars are s.e.m. ns, not significant; \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.005. pp, preplate; vz, ventricular zone. Scale bars: 125 μm.

We first asked whether *Plag1* and/or *Plagl2* could promote ectopic proliferation by assessing the incorporation of BrdU administered 30 min before embryo collection. Relative to control E12.5→E13.5 electroporations, *Plagl2* (and not *Plag1*) was sufficient to increase the number of cells taking up BrdU (i.e. BrdU^+^GFP^+^/GFP^+^ cells; *n*=3; *P*\<0.05; [Fig. 7](#BIO038661F7){ref-type="fig"}B--E). Similarly, *Plagl2* misexpression increased the number of cortical progenitors expressing pHH3, a G2/M-phase marker (*n*=3; *P*\<0.001; [Fig. 7](#BIO038661F7){ref-type="fig"}F--I), whereas *Plag1* did not alter the pHH3^+^GFP^+^/GFP^+^ ratio. However, this increase in proliferation did not translate into an increase in RGC progenitor cells, as the ratio of Pax6^+^GFP^+^/GFP^+^ cells was not altered by either *Plag1* or *Plagl2* (*n*=3 each; [Fig. 7](#BIO038661F7){ref-type="fig"}J--M). Moreover, there was a decrease, rather than increase, in the number of Tbr2^+^GFP^+^/GFP^+^ INPs generated after the misexpression of both *Plag1* (*n*=3; *P*\<0.05) and *Plagl2* (*n*=3; *P*\<0.01) ([Fig. 7](#BIO038661F7){ref-type="fig"}N--Q).

In summary, *Plagl2* but not *Plag1* is sufficient to induce the proliferation of neocortical progenitors, at least within a short 24 h time window.

*Plag1* and *Plagl2* inhibit neuronal differentiation 72 h post-electroporation, and *Plag1* has a delayed effect on increasing the BrdU labelling {#s2i}
--------------------------------------------------------------------------------------------------------------------------------------------------

To assess the effects of *Plag1* and *Plagl2* on neuronal differentiation and migration, we introduced *Plag1* and *Plagl2* expression vectors (and pCIG2 control) into E12.5 neocortical progenitors via *in utero* electroporation, but this time we assessed electroporated brains at E15.5, 72 h post-electroporation. The positions of the GFP^+^ electroporated cells were compared by counting labeled cells in the VZ, SVZ, intermediate zone (IZ) and cortical plate (CP). In control electroporations, most GFP^+^ labeled cells had already reached the CP 72 h post-electroporation ([Fig. 8](#BIO038661F8){ref-type="fig"}A,D). In contrast, E12.5→E15.5 electroporations of *Plag1* ([Fig. 8](#BIO038661F8){ref-type="fig"}B) and *Plagl2* ([Fig. 8](#BIO038661F8){ref-type="fig"}C) differed, in that more GFP^+^ electroporated cells were concentrated in the SVZ (*n*=3; *P*\<0.001 for *Plag1* and *P*\<0.01 for *Plagl2*; [Fig. 8](#BIO038661F8){ref-type="fig"}D) and IZ (*n*=3; *P*\<0.001 for *Plag1* and *Plagl2*; [Fig. 8](#BIO038661F8){ref-type="fig"}D), and fewer GFP^+^ cells reached the CP (*n*=3; *P*\<0.001 for *Plag1* and *Plagl2*; [Fig. 8](#BIO038661F8){ref-type="fig"}D). Overexpression of either *Plag1* or *Plagl2* thus strongly perturbs cellular migration, either because overexpressing cells fail to undergo neurogenesis, and/or because these genes impede neuronal migration. Fig. 8.***Plag1* and *Plagl2* are sufficient to induce migration defects, and alter proliferation and differentiation when misexpressed in the neocortex 72 h post electroporation.** (A--L) E12.5 to E15.5 electroporations of pCIG2 (A,E,I), *Plag1* (B,F,J) and *Plagl2* (C,G,K) analyzed for the expression of GFP in different zones (A--D), and the co-expression of GFP with Tbr1 (E--H) and BrdU (I--L). Quantitation of the ratios of GFP^+^ cells that are in each zone (D), Tbr1^+^ (H) and BrdU^+^ (L). Error bars are s.e.m. ns, not significant; \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.005. cp, cortical plate; iz, intermediate zone; svz, subventricular zone; vz, ventricular zone. Scale bars: 125 μm.

To assess the effects of *Plag1* and *Plagl2* on neurogenesis in the E12.5 neocortex, at 72 h post-electroporation (at E15.5) we examined the expression of Tbr1 ([Fig. 8](#BIO038661F8){ref-type="fig"}E--G), which is expressed at high levels in deep-layer neocortical neurons ([@BIO038661C32]). In E12.5→E15.5 electroporations the number of *Plag1-* and *Plagl2*-transfected cells that expressed Tbr1 was reduced compared to pCIG2 transfections (*n*=3; *P*\<0.001 for both genes; [Fig. 8](#BIO038661F8){ref-type="fig"}E--H). These data suggested that *Plag1* and *Plagl2* do indeed block neuronal differentiation in the neocortex, and the inability of these cells to differentiate likely results in their migratory defects.

The inability of *Plagl2-*overexpressing progenitors to differentiate was consistent with the increased mitotic activity of these cells 24 h post-electroporation, whereas *Plag1* misexpression did not have the same effect after 24 h ([Fig. 7](#BIO038661F7){ref-type="fig"}E,I). To test whether *Plag1* and *Plagl2* influenced the proliferative capacity of E12.5 cortical progenitor cells 72 h post-electroporation, we performed a 30 min pulse-label with BrdU ([Fig. 8](#BIO038661F8){ref-type="fig"}I--L). In E12.5→E15.5 electroporations there were more GFP^+^BrdU^+^ S-phase progenitors in *Plag1* electroporations compared to pCIG2 control and *Plagl2* transfections (*n*=3; *P*\<0.001; [Fig. 8](#BIO038661F8){ref-type="fig"}I--L). *Plag1*-misexpressing cells thus proliferate more and differentiate less, even though they take longer to initiate BrdU uptake compared to *Plagl2*-overexpressing cells.

DISCUSSION {#s3}
==========

In this study we investigated the functions of the proto-oncogenes *Plag1* and *Plagl2* in the developing telencephalon. Our goal was to generate double mutants to assess genetic redundancy, but no live *Plag1;Plagl2* double-mutant embryos were collected at E12.5, indicating that these genes can compensate for one another with respect to overall embryonic growth and survival and that at least one gene copy of either *Plag1* or *Plagl2* is required. Furthermore, we found that the *Plagl2* genotype was early-embryonic lethal on a CD1 background, with a reduced number of single mutant embryos obtained at E12.5, restricting our analyses of telencephalic development to this early embryonic stage. Our analysis of E12.5 mutants revealed differences in the functions of *Plag1* and *Plagl2,* including an unexpected and striking patterning defect in the *Plagl2* mutant telencephalon, indicating that this gene is required to set the ventral boundary of dorsal gene expression. In contrast, *Plag1* is necessary to regulate the balance between proliferation and neuronal differentiation in the developing neocortex.

The *Plagl2* mutant patterning defect was somewhat unexpected as we observed an expansion of the ventral pallium without a corresponding decrease in the size of the dLGE, a territory immediately adjacent to the ventral pallium. This phenotype contrasts to defects observed upon the mutation of other patterning genes, including *Pax6* and *Gsx2*, which result in compensatory changes in the sizes of these two domains; in *Pax6* mutants, the dLGE expands at the expense of the ventral pallium, whereas the opposite phenotype is observed in *Gsx2* mutants ([@BIO038661C100]). There is also a repression of a ventral pallial identity upon the deletion of *Nr2e1*, also called *Tlx* (*tailless*), resulting in the loss of *Sfrp1* and *Dbx1* expression ([@BIO038661C78],[@BIO038661C79]). Complex genetic interactions thus regulate the establishment of these two important telencephalic domains, and *Plagl2* is an important determinant of ventral pallial domain size. Of note, while we did not observe a reduction in the number of Tbr1^+^ neurons in the presumptive piriform cortex in *Plagl2* mutants, which is derived from the ventral pallium, it may be that analyses at later stages could reveal defects. We were, however, precluded from these later studies by the early embryonic lethality of the *Plagl2* mutation.

While we did not observe patterning defects in *Plag1* mutants, we did observe that this gene is essential for neocortical progenitor proliferation and to block neuronal differentiation, consistent with its known role as a growth regulator. Interestingly, in gain-of-function studies, *Plag1* promotes BrdU uptake and reduces neurogenesis, but the effects on BrdU incorporation were delayed and only revealed 72 h post-electroporation. In contrast, *Plagl2* very rapidly induced BrdU uptake in E12.5 neocortical progenitors, within 24 h post-electroporation. While BrdU incorporation is a measure of all progenitors that are in S-phase of the cell cycle, it cannot be used to distinguish between those progenitors that are about to differentiate versus those that will continue to proliferate. However, taken together with the effects on differentiation, our data highly supports the idea that *Plag1* and *Plagl2* overexpression tips the balance towards more proliferative cell divisions in the early embryonic neocortex.

In summary, despite their related structures and roles as proto-oncogenes, there are key differences in how *Plag1* and *Plagl2* function *in vivo*. We discuss the potential reasons for these differences below, and compare *Plag1* and *Plagl2* functions to *Plagl1* (also known as *Zac1*), the third member of this gene family.

All three of the Plag proteins transactivate some common transcriptional targets, including several imprinted genes (e.g. *Dlk1*, *Igf2*) ([@BIO038661C28]; [@BIO038661C89]; [@BIO038661C91]; [@BIO038661C95]; [@BIO038661C101]), despite Plag1 and Plagl2 recognizing a distinct binding site (GRGGCN~6-8~G~3~) ([@BIO038661C42]; [@BIO038661C56]; [@BIO038661C94]) compared to Zac1 (G~4~C~4~, G~4~N~6~G~4~ or GC~2~GC~2~G) ([@BIO038661C47]; [@BIO038661C90]; [@BIO038661C99]). Given the similar transcriptional targets, it is surprising that *Plag1* and *Plagl2* act as proto-oncogenes, while *Zac1* is a tumor suppressor gene. Moreover, *Zac1* misexpression was previously shown to reduce proliferation in the neocortex ([@BIO038661C4]; [@BIO038661C74]), whereas in this study we showed that both *Plag1* and *Plagl2* were sufficient to promote BrdU uptake and block neurogenesis.

One possible reason for these functional differences despite overlapping transcriptional targets is that Zac1 can function as a transcriptional activator or repressor ([@BIO038661C47]; [@BIO038661C90]; [@BIO038661C99]). When Zac1 binds as a monomer, it transactivates G~4~C~4~ and GC~2~GC~2~G sites and represses transcription from G~4~N~6~G~4~ sites, while dimer binding to G~4~N~6~G~4~ leads to transactivation ([@BIO038661C47]; [@BIO038661C99]). Zac1 transcriptional activity is also modulated by interactions with nuclear importers ([@BIO038661C51]), other transcription factors ([@BIO038661C99]), and histone acetyltransferases (HAT) ([@BIO038661C48]). Zac1 can also act in a non-DNA binding-dependent manner, functioning as a co-activator or co-repressor of other transcriptional regulators \[e.g. p53, nuclear receptors; [@BIO038661C47]; [@BIO038661C50]; [@BIO038661C49]; [@BIO038661C56]; [@BIO038661C61]; [@BIO038661C73]; [@BIO038661C99]\].

In addition to sharing some common targets, the three transcription factors must also transactivate distinct genes in the developing telencephalon. Some studies have begun to identify transcriptional targets for *Plag1* ([@BIO038661C95]), *Plagl2* ([@BIO038661C104]) and *Zac1* ([@BIO038661C74]; [@BIO038661C92], [@BIO038661C91]), but which of these genes are important in telencephalic development will require further study. *Zac1* misexpression was shown to upregulate the expression of several imprinted genes, consistent with the finding that *Zac1* is part of an imprinted gene network ([@BIO038661C91]). *Zac1* also induced the expression of negative regulators of the cell cycle, such as the cyclin dependent kinase inhibitors p57 (which is imprinted) and p27, consistent with the ability of *Zac1* to promote cell cycle exit ([@BIO038661C74]). Finally, *Zac1* misexpression also induced the ectopic expression of several genes not normally expressed in neural lineages, as well as genes associated with pluripotency, suggesting that one function of *Zac1* is to promote a pluripotent state ([@BIO038661C74]). It will be of interest in the future to see whether *Plag1* and *Plagl2* also have a similar role in maintaining pluripotency.

We found that *Plag1* is required to regulate cell proliferation in the neocortex, which is of particular interest as several genome wide association studies (GWAS) have indicated that a SNP in *Plag1* is in one of 27 loci that correlate with height in humans ([@BIO038661C99]), and additional studies have found correlations with stature or size in various livestock species, including cattle, pigs and horses ([@BIO038661C52]). While these are association studies, the underlying assumption is that *Plag1* is an important regulator of growth. Interestingly, in our gain-of-function studies, *Plag1* was not sufficient to promote proliferation in neocortical progenitors, possibly because it acts in concert with other factors to carry out its growth regulatory role. Igf2 is a downstream transcriptional target of *Plag1* that has been implicated in growth control ([@BIO038661C94]), and it may be that *Plag1* is not sufficient on its own to turn on this transcriptional target in the embryonic neocortex. Another possibility is that Plag1 is sumoylated in the embryonic neocortex, as this post-translational modification has been shown to repress the ability of Plag1 to transactivate downstream targets ([@BIO038661C86]).

In our study we found that *Plagl2* is sufficient but not necessary to promote the proliferation of neocortical progenitor cells. This data is consistent with a previous report showing that misexpression of *Plagl2* in *p53*^−/−^ adult neural stem cells promotes a proliferative phenotype when these cells are cultured *in vitro*, with the enriched expression of G1/S cell cycle checkpoint genes ([@BIO038661C104]). Moreover, we found that *Plagl2* reduces neuronal differentiation in the embryonic telencephalon, similar to how it functions in glioma cells ([@BIO038661C104]). These results suggest that *Plagl2* functions are context-dependent. Indeed, *Plagl2* is not oncogenic in all contexts \[e.g. pro-apoptotic in response to hypoxia and other cellular stresses [@BIO038661C36]; [@BIO038661C39]; [@BIO038661C64]; [@BIO038661C98]\]. One reason why *Plagl2* functions may change in different contexts is that its transcriptional activity is also regulated by post-translational modifications, including sumoylation and acetylation ([@BIO038661C40]; [@BIO038661C66]; [@BIO038661C86]; [@BIO038661C103]). Under the right conditions, *Plagl2* may promote neocortical progenitor proliferation possibly via its capacity to initiate the transcription of Wnt pathway genes ([@BIO038661C104]), a key proliferative signal in the neocortex ([@BIO038661C104]).

In summary, our study reveals that *Plag1* and *Plagl2* are not only important regulators of tumorigenesis, but also play important redundant as well as complementary roles in normal CNS development and embryonic survival.

MATERIALS AND METHODS {#s4}
=====================

Animals {#s4a}
-------

The use of animals was vetted and approved by the University of Calgary and then the Sunnybrook Research Institute Animal Care Committees in agreement with the Guidelines of the Canadian Council of Animal Care (CCAC). The generation of *Plag1^lacZ^*^KI^ ([@BIO038661C43]) and *Plagl2^lacZ^*^KI^ ([@BIO038661C87]) mice was previously reported and we maintained these mutant alleles on a CD1 background. For *Plag1* genotyping we used the following cycles: 95°C 4 min, 40× (95°C 1 min, 55°C 1 min, 72°C 1.5 min), 72°C 10 min. *Plag1* genotyping primers for the wild-type allele were: *Plag1* WT forward primer: 5′-CGGAAAGACCATCTGAAGAATCAC-3′. *Plag1* WT reverse primer: 5′-CGTTCGCAGTGCTCACATTG-3′. *Plag1* genotyping primers for the mutant allele were: *Plag1* mutant forward primer: 5′-CGGAAAGACCATCTGAAGAATCAC-3′. *Plag1* mutant reverse primer: 5′-AATGTGAGCGAGTAACAACCCG-3′. For *Plagl2* genotyping we used the following cycles: mutant: 95°C 4 min, 35× (95°C 1 min, 62°C 1 min, 72°C 1.5 min), 72°C 10 min. Wild type: 95°C 4 min, 40× (95°C 1 min, 59°C 1 min, 72°C 1.5 min), 72°C 10 min. *Plagl2* genotyping primers for the wild-type allele were: *Plagl2*WT forward primer: 5′-TGTATGGTGCCCACATCCCTAC-3′. *Plagl2*WT reverse primer: 5′-GGAAAAGTCCACATTAGCAGCG-3′. *Plagl2* genotyping primers for the mutant allele were: *Plagl2* MUT forward primer: 5′-CAGTTCAACATCAGCCGCTACAG-3′. *Plagl2* MUT reverse primer: 5′-GGTGGACAGTGGACATTTATCAAGG-3′.

Tissue processing and cryostat sectioning {#s4b}
-----------------------------------------

Embryos were dissected at E12.5 for all loss-of-function studies and at E13.5 for gain-of-function studies. Embryos were fixed overnight at 4°C in 4% paraformaldehyde (PFA) diluted in phosphate buffered saline (PBS) at pH 7.5. To remove the fixative, embryos were washed three times for 10 min in PBS, and then transferred to 20% sucrose/1× PBS overnight. For cyrosectioning, the brains were embedded in optimal cutting temperature (OCT) compound and stored at −80°C. Blocks were then sectioned at 10 µm on a cryostat for immunostaining and RNA *in situ* hybridization.

Immunohistochemistry {#s4c}
--------------------

For immunostaining, sections were blocked in 10% Horse Serum, 0.1% Triton-X100 in PBS (PBT) at pH 7.5 for 1 h. Primary antibodies were then diluted in blocking solution and the sections were incubated overnight at 4°C. Primary antibodies included rabbit anti-Tbr1 (1:800, Chemicon; Etobicoke, ON, Canada), rabbit anti-GFP (1:500, Chemicon, Temecula, CA, USA), goat-anti-GFP (1:1000, Abcam) rabbit anti-Pax6 (1:500, Convance), goat anti-Gsx2 (1:500, Millipore), rabbit anti-Tbr2 (1:500, Abcam), rabbit anti-phospho-histone H3 (pHH3; 1:500; Millipore Biotechnology) and rat anti-BrdU (1:20, Serotec). After incubating in primary antibody, the slides were washed three times in PBT and then incubated for 1 h at room temperature in secondary antibodies. Secondary antibodies were conjugated to Alexa568 (1:500; Molecular Probes) or Alexa488 (1:500; Molecular Probes). After incubation with secondary antibodies, the slides were washed three times in PBS and then stained with DAPI (1/10,000 for 5 min) and washed an additional three times. Slides were mounted in Aqua-polymount for imaging.

BrdU labeling {#s4d}
-------------

100 µg/g body weight BrdU (Sigma-Aldrich) was injected intraperitoneally 30 min before the mice were euthanized. Prior to immunolabeling, sections were immersed in 2 N HCl for 15 min at 37°C ([@BIO038661C16]). Immunolabeling was then performed as described.

RNA *in situ* hybridization {#s4e}
---------------------------

RNA *in situ* hybridization was performed on 10 mm cryosections using a previously described protocol ([@BIO038661C84]). Riboprobes were described in the following publications; *Plag1* and *Plagl2* ([@BIO038661C6]), *Dlx1* ([@BIO038661C7]), *Ascl1* ([@BIO038661C18]), *Neurog2* ([@BIO038661C38]), *Etv1* ([@BIO038661C29]), *Sp8* ([@BIO038661C96]) and *Dbx1* ([@BIO038661C31]).

X-Gal staining {#s4f}
--------------

Slides were washed with DEPC phosphate buffered saline (PBS) pH7.5 for 5 min, three times. Sections were fixed in fixing solution (0.2% glutaraldehyde, 2% formaldehyde, 5 mM EGTA pH7.3, 2 mM magnesium chloride and 0.1 M sodium phosphate pH7.3 in PBS) for 15 min at room temperature. The slides were then washed with washing solution (0.02% NP40, 2 mM MgCl~2~ in PBS) for 10 min, three times. The slides were immersed in prewarmed staining solution \[20 mg/ml X-gal-Sigma-Aldrich B4252 dissolved in DMSO, 5 mM K~3~Fe(CN)~6~, 5 mM K~4~Fe(CN)~6~, 2 mM MgCl~2~, 0.02% NP40 in PBS\] and incubated in a 37°C water bath for 4 h to overnight protected from light. The tissues were dehydrated in 95% and 100% EtOH, and Xylene at room temperature. After the slides were dry, ∼4 drops of permount was added per slide and mounted with a coverslip for imaging.

*In utero* electroporation {#s4g}
--------------------------

We performed *in utero* electroporation as previously described ([@BIO038661C30]; [@BIO038661C59]). Briefly, we introduced 3 μg/μl of a pCIG2 control vector, which expresses GFP, or 3 μg/μl of pCIG2-*Plag1* or pCIG2-*Plagl2*, which express the gene of interest and GFP, into E12.5 telencephalic vesicles using borosilicate needles and a Femtojet microinjector. Using a BTX electroporator, we applied 7 pulses of 55 mV within a 7 s interval to the uterus with the paddles flanking the head of the embryo. The uterus was then put back and embryos underwent normal development until E13.5. pCIG2-*Plag1* was generated by PCR amplification of *Plag1* from IMAGE clone ID 6328180 using the following primers: *Plag1*L: AATCTAGAGATGGCCACTGTCATTCCTGG; *Plag1*R: AATCTAGAGGCTACACAAGCA CCTCGGGT. The amplified *Plag1* cDNA was cloned as a blunted *Xba*I fragment into the blunted *EcoR*I site of pCIG2. pCIG2-*Plagl2* was generated by PCR amplification of *Plagl2* from IMAGE clone ID 6405960 using the following primers: *Plagl2*L: AATCTAGACATGACCACATTTTT CACCAG; *Plagl2*R: AATCTAGACTGAGTTGGGGGACCTTCAT. The amplified *Plagl2* cDNA was cloned was cloned directionally as an *EcoR*I fragment into the *EcoR*I site of pCIG2.

RT-qPCR {#s4h}
-------

We microdissected the dorsal telencephalon from E12.5 embryos as described. RNA was extracted with TRIzol reagent following the instructions of the manufacturer (Thermo Fisher Scientific, Cat\#15596026). cDNA was synthesized and RT-qPCR was performed using a RT2 primer assay kit (Qiagen, 330001) according to the manufacturer\'s instructions. The following RT^2^ qPCR primers were obtained from Qiagen: *Gapdh* (PPM02946E), *B2m* (PPM03562A), *Hrpt* (PPM03559F), *Plag1* (PPM30678A), *Plagl2* (PPM30603B) and *Zac1* (PPM03537F). qPCR was performed with cortices from three embryos of each genotype and with three technical replicates for each biological replicate. We used the delta-delta Ct method to calculate relative expression levels, using three housekeeping genes to normalize (*Gapdh*, *B2M*, *Hrpt*).

Imaging, quantitation and statistics {#s4i}
------------------------------------

We captured images using OpenLab5 software (Improvision) and a QImaging RETIGA EX digital camera for bright-field images and a Leica DMRXA2 optical microscope for fluorescence imaging. Images were processed in Photoshop CS6 (64 bit; Adobe Systems) and quantification was performed from these images. For quantification we used a minimum of three embryos, and three sections per embryo. Calculation of statistical significance involved a one-way ANOVA with a Tukey correction for multiple comparisons. Graphs and statistical values were generated using GraphPad Prism software.
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